EyePoint, Inc.
EyePoint, Inc. (Nasdaq: EYPT) is a biopharmaceutical company developing and commercializing treatments for serious retinal diseases. Its pipeline centers on DURAVYU, an investigational sustained-delivery intravitreal treatment combining vorolanib with the bioerodible Durasert E technology; Phase 3 trials evaluate it… From the company’s description.
Over the twelve months to Jun 30, 2026, EyePoint, Inc. reported revenue of $2.79M, down 94.6% from a year earlier, and a net loss of $306.64M. Operations used $267.30M in cash. In fiscal 2025, it reported revenue of $31.37M, down 27.5% from fiscal 2024, and a net loss of $231.96M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What EyePoint, Inc. does
In the company’s own words
EyePoint, Inc. (Nasdaq: EYPT) is a biopharmaceutical company developing and commercializing treatments for serious retinal diseases. Its pipeline centers on DURAVYU, an investigational sustained-delivery intravitreal treatment combining vorolanib with the bioerodible Durasert E technology; Phase 3 trials evaluate it for wet age-related macular degeneration and diabetic macular edema. The company is also advancing EYP-2301, a preclinical program delivering razuprotafib for potential treatment of serious retinal diseases. EyePoint’s Durasert technology is designed to release drugs over time following injection, and has been used in four FDA-approved products. Its marketed product portfolio includes YUTIQ and DEXYCU; the company manufactures YUTIQ and supplies products under a commercial agreement. Ophthalmologists and their patients are central to its product and development focus. EyePoint operates as a single business focused on ophthalmic therapeutics, with research, clinical development, manufacturing and commercialization activities. Its lead candidate’s Phase 3 programs target two major retinal conditions, while its platform supports development across additional eye diseases.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1314102
- SIC
- 3826
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns EyePoint, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · EyePoint, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do EyePoint, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of EyePoint, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in EyePoint, Inc.'s last four quarterly filings that the numbers alone won't show?”